You are visiting us from Virginia. You are located in HHS Region 3. Your Center is Central East ATTC.

AMERSA People & Passion, Episode 3: Barriers to Treatment for Opioid Use Disorder: Why Aren’t Pharmacists Stocking Buprenorphine?

Patients with opioid use disorder must be able to obtain prescribed buprenorphine from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. However, phone-based secret shopper surveys indicate many pharmacies do not consistently maintain an adequate stock of buprenorphine and qualitative surveys show some pharmacists refuse to dispense it altogether. The underlying reasons for this problem are complex and will require innovative collaborations between pharmacists, buprenorphine prescribers, policymakers, and other healthcare team members.



Photo of Jeffrey Bratberg

Jeffrey P. Bratberg, PharmD, Clinical Professor at the University of Rhode Island, studies community pharmacists' roles play regarding opioid safety, opioid overdose, harm reduction and opioid use disorders. He is a consultant or co-investigator on two federal grants, a randomized controlled trial of pharmacists’ use of a CPA to manage medications for opioid use disorder and a multi-state, randomized control trial testing the effectiveness of a pharmacist and pharmacy focused intervention to improve naloxone provision, nonprescription syringe access and buprenorphine dispensing in community pharmacies.

Lucas G. Hill, PharmD, BCPS, BCACP serves as PhARM Director, The University of Texas at Austin. Dr. Hill graduated from the UMKC School of Pharmacy and completed a combined residency/fellowship in the UPMC Department of Family Medicine. He is now a clinical assistant professor at The University of Texas at Austin College of Pharmacy where he founded the PhARM Program and led implementation of Operation Naloxone. Dr. Hill is the principal investigator for a five-year, $25 million TTOR grant which seeks to address the opioid crisis in Texas by educating health professionals and the public while conducting pragmatic research. 

Photo of Lindsey LoeraLindsey J. Loera, PharmD is a PhARM Fellow at The University of Texas at Austin. Dr. Loera graduated from The University of Texas at Austin College of Pharmacy and is currently completing a two-year fellowship with the PhARM Program. In this role, she will develop an innovative clinical pharmacy practice at an outpatient medical home for SUD and conducts statewide research exploring the pharmacist’s role in addiction treatment. She previously served as President of the Student Pharmacist Recovery Network and co-founded the Addiction Medicine Advanced Pharmacy Practice Experience.

Published:
09/22/2021
Tags
Recent posts
This flipbook features a compilation of published blog posts from the ATTC/NIATx Service Improvement Blog that highlights content focused on the use of NIATx principles, tools, and processes to create impactful and lasting organizational change. It also includes information on implementing the NIATx change model in new and diverse settings. By compiling the content according to these […]
Prevention coalitions often face challenges engaging parents in prevention initiatives, even when those efforts address critical issues like youth substance use or mental health. Here's an example of how a fictional coalition decided to take on this challenge by using the NIATx Plan-Do-Study-Act (PDSA) tool. The small, incremental changes they made helped to increase attendance […]
The flowchart is one of the essential tools in the NIATx model. A flowchart provides visual map of your process—it shows how things get done, step by step. You might be thinking, “Why do we need a flowchart if we already did a walk-through of the process?" If the process seems straightforward, your team might […]
Xylazine, medetomidine and nitazines are substances that are emerging as key contributors in the latest wave of the Opioid Overdose Epidemic. Xylazine is an adulterant that increases the duration of a user’s fentanyl high and delays withdrawal to some extent. Medetomidine is another adulterant that belongs to the same family of drugs as xylazine, but […]

The opinions expressed herein are the views of the authors and do not reflect the official position of the Department of Health and Human Services (DHHS), SAMHSA, CSAT or the ATTC Network. No official support or endorsement of DHHS, SAMHSA, or CSAT for the opinions of authors presented in this e-publication is intended or should be inferred.

map-markermagnifiercrossmenuchevron-down